STAT5B and mature T-cell and NK-cell non-Hodgkin lymphoma: Our data suggest that PTCL patients with activating STAT5 mutations could benefit from STAT5 inhibitors either as mono-therapy or in combination with additional therapeutic strategies to provide more efficacious, less toxic treatment.